Reported results
- Net revenues for the third quarter 2026 were $84.7 million, compared to $49.5 million for the third quarter 2025.
- GAAP net loss for the third quarter 2026 was $13.9 million, compared to $30.0 million for the third quarter 2025.
- Non-GAAP adjusted net income for the third quarter 2026 was $3.0 million, compared to a non-GAAP adjusted net loss of $11.2 million for the same period in 2025.
- Non-GAAP operating expenses, excluding stock-based compensation, were $60.5 million for the third quarter 2026, compared to $49.3 million for the third quarter 2025.
- Approximately 380,000 total VOQUEZNA prescriptions were filled during the third quarter 2026.
Guidance
- Full-year 2026 net revenue: $310–325 million
- Full-year 2026 gross-to-net discount: 55–59%
- Full-year 2026 gross margin: ~80%
- Full-year 2026 non-GAAP operating expenses, excluding stock-based compensation: $235–245 million
Price and volatility reaction
The stock moved -1.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -46.0 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 6.28 | 2026-10-28 |
| Close after release | 6.22 | 2026-10-29 |
| Realised move | -1.0% | close to close |
| 30d ATM IV change | -46.0 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
